Showing 561 - 580 results of 858 for search 'Liu Wuzhou~', query time: 1.58s Refine Results
  1. 561
  2. 562
  3. 563
  4. 564
  5. 565

    Phage vB_Kpn_HF0522: Isolation, Characterization, and Therapeutic Potential in Combatting K1 Klebsiella pneumoniae Infections by Yan T, Wang Q, Ma C, Teng X, Gong Z, Chu W, Zhou Q, Liu Z

    Published 2025-02-01
    “…Tao Yan,1,2 Qiuyan Wang,2 Chengcheng Ma,2 Xuan Teng,2 Zhen Gong,2 Wenwen Chu,2 Qiang Zhou,2 Zhou Liu1 1Department of Clinical Laboratory Center, Anhui Chest Hospital, Hefei, 230031, People’s Republic of China; 2Department of Clinical Laboratory, the Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, People’s Republic of ChinaCorrespondence: Zhou Liu, Department of Clinical Laboratory Center, Anhui Chest Hospital, Hefei, People’s Republic of China, Email liuzhou0112@ahmu.edu.cnPurpose: Klebsiella pneumoniae is a globally prevalent pathogen responsible for severe hospital- and community-acquired infections, and presents significant challenges for clinical management. …”
    Get full text
    Article
  6. 566
  7. 567
  8. 568
  9. 569
  10. 570
  11. 571

    Effects of Food on the Pharmacokinetics and Safety of HA121-28 Tablet, a Novel Multi-Targeting Tyrosine Kinase Inhibitor, in Healthy Chinese Subjects: A Phase I Clinical Trial by Liu Y, Li X, Zhang M, Men Y, Wang Y, Zhu X, Zheng L

    Published 2025-01-01
    “…Yixian Liu,1,2,* Xiaoyu Li,1,2,* Mengyu Zhang,1,2 Yuchun Men,1,2 Ying Wang,1,2 Xiaohong Zhu,1,2 Li Zheng1,2 1Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, People’s Republic of China; 2Clinical Trial Center, NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, West China Hospital, Sichuan University, Chengdu, 610041, People’s Republic of China*These authors contributed equally to this workCorrespondence: Li Zheng, Cancer Center, West China Hospital, Sichuan University, No. 5 Telecom Road, Wuhou District, Chengdu, 610041, People’s Republic of China, Email zhengli@wchscu.cnPurpose: HA121-28, a novel multi-targeting tyrosine kinase inhibitor, has dual efficacy against tumor growth and neovascularization. …”
    Get full text
    Article
  12. 572
  13. 573
  14. 574
  15. 575
  16. 576
  17. 577
  18. 578
  19. 579
  20. 580